Vivek Subbiah/LinkedIn
Apr 19, 2025, 08:05
Vivek Subbiah: Safety and activity of fibroblast growth factor receptor inhibitors in advanced malignancies
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, posted on LinkedIn about recent paper he and his colleagues co-authored:
“Delighted to share our latest publication in American Society of Clinical Oncology (ASCO) Journal JCO Precision Oncology – courtesy of our brilliant colleagues from London led by Dr. Elisa Fontana.
FGFR is clearly a tissue-agnostic target but we need to find the right dose for the right patient with right alteration.
Thrilled to collaborate with amazing colleagues Tobias Arkenau, Charles Swanton.”
Authors: Rafael Grochot, Tobias Arkenau, Charles Swanton, Vivek Subbiah, Elisa Fontana, et al.
More posts featuring Vivek Subbiah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 9, 2025, 16:50
Jul 9, 2025, 16:44
Jul 9, 2025, 16:36
Jul 9, 2025, 16:15